Aqua Pharmaceuticals Acquires Verdeso® Foam
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WEST CHESTER, Pa.--(BUSINESS WIRE)--West Chester-based Aqua Pharmaceuticals today announces the acquisition of U.S. rights to, and re-launch of, Verdeso® (desonide) Foam, 0.05% from Stiefel, a GSK company (“GSK”). Verdeso® Foam is the only low-potency corticosteroid foam indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. The emollient-based and ethanol-free Verdeso® Foam is unavailable in generic form. Aqua will assume control of all manufacturing and distribution, as well as promotion of the product through its own national dermatology-specialty sales force.
Help employers find you! Check out all the jobs and post your resume.
WEST CHESTER, Pa.--(BUSINESS WIRE)--West Chester-based Aqua Pharmaceuticals today announces the acquisition of U.S. rights to, and re-launch of, Verdeso® (desonide) Foam, 0.05% from Stiefel, a GSK company (“GSK”). Verdeso® Foam is the only low-potency corticosteroid foam indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. The emollient-based and ethanol-free Verdeso® Foam is unavailable in generic form. Aqua will assume control of all manufacturing and distribution, as well as promotion of the product through its own national dermatology-specialty sales force.
Help employers find you! Check out all the jobs and post your resume.